643 results about "Dimer" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses an arginine decarboxylase diaA enzyme mutant and application thereof in preparation of butanediamine, and belongs to the field of bioengineering. According to the invention, rational charge overturning transformation is simultaneously carried out on a pentamer meridian oligomeric interface and a dimer latitudinal oligomeric interface, so that stable assembly and efficient catalysis of the decamer under the condition of neutral to alkaline pH (7.0-9.0) are realized. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD110K / H736E at pH 8.0 is about 35 times that of a wild type, and the representative double mutant AdiAD110K / H736E keeps a complete decamer state in a pH range of 7.0-9.0. The yield of butanediamine is up to 145.9 g / L under the whole-cell catalysis of the mutant.

The invention discloses a rational copolymerization strategy for improving the stability of an oligomeric structure of acid-induced high-order oligomeric decarboxylase AdiA in a neutral to alkaline environment and application of the rational copolymerization strategy, and belongs to the field of bioengineering. According to the strategy, rational charge overturning transformation is carried out on a pentamer radial oligomeric interface and a dimer weft-wise oligomeric interface at the same time, and stable assembly and efficient catalysis of a decamer under the condition that the pH value is from 7.0 to 9.0 from neutral to alkaline are achieved. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD471K / E467K / H736E is 45.5 times that of a wild type when the pH value is 8.0, and the representative double mutant AdiAD471K / E467K / H736E keeps a complete decamer state when the pH value is 7.0-9.0. The yield of butanediamine is up to 156.5 g / L by using the mutant to catalyze whole cells.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention belongs to the field of nucleic acid detection and molecular biology, and particularly relates to a method and a kit for eliminating false positive results in nucleic acid amplification reaction. According to the method, after a nucleic acid amplification reaction (taking recombinase polymerase amplification, namely RPA, for example) is completed, a target amplification product is subjected to selective enzyme digestion by utilizing restriction endonuclease, non-target products (such as primer dimers and non-specific amplification products) are not cut, and meanwhile, the non-target products which are not subjected to enzyme digestion are removed by combining solid-phase separation, so that the target amplification product is obtained. Therefore, the false positive result is eliminated. The invention also discloses a kit containing the restriction enzyme. According to the method, the specificity and the signal-to-noise ratio of a nucleic acid amplification reaction, especially RPA, are remarkably improved, the cost is low, operation is easy, the method is compatible with an existing technical platform, the method is suitable for detection scenes such as clinical molecular diagnosis, environmental monitoring and food safety, and the problem of misjudgment caused by false positive signals is effectively avoided.

The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and / or CL domains, in the VH and / or VL domains, or a combination thereof.

The invention relates to an islet repair ICK mode oral polypeptide optimization system taking VDAC1 as a target based on ESM2 and a genetic algorithm, and the system comprises a mutation module which is used for carrying out mutation and recombination by adopting the genetic algorithm according to original protein sequence data to generate an initial population; the prediction module is used for respectively inputting the protein sequence data of the initial population into a protein dimer dissociation energy prediction model, a protein toxicity prediction model and a protein cell penetrability prediction model to obtain a dissociation energy prediction value delta G, a toxicity probability value T and a cell membrane passing transmission probability Ed; and the optimization module is used for acquiring the optimal individual performance of the highest fitness score to output the Pareto optimal sequence index, and recording the hotspot residue distribution and the site mutation frequency at the same time. On the basis of keeping the biological activity of the original sequence, the key drug properties are improved in a breakthrough manner.

The invention discloses a low dimer modified isocyanate composition and a preparation method thereof. The content of dimers in the modified isocyanate is reduced to 0.9 wt% or below mainly by controlling the reaction temperature of carbodiimide, the cooling rate after the reaction and the curing temperature. Through the method, the storage time of the modified isocyanate can be prolonged, and the stability of the modified isocyanate product is improved.

Provided is a method for producing a heterodimeric protein such as a bispecific antibody with which a heterodimeric protein composed of only domains having natural amino acid sequences can also be produced. A production method of the present invention is a method for producing a heterodimeric protein. The production method includes a production step of producing a heterodimeric protein by reacting a dimeric protein having a reaction tag with a modification protein for modifying the dimeric protein. The dimeric protein having a reaction tag includes a first monomeric protein and a second monomeric protein. The first monomeric protein includes a first reaction tag and a first dimer formation domain capable of forming a dimer in this order. The first reaction tag includes a binding tag and a first C intein. The second monomeric protein includes a second reaction tag and a second dimer formation domain capable of forming a dimer together with the first dimer formation domain in this order. The second reaction tag includes a binding partner capable of binding to the binding tag, and a second C intein. The modification protein includes a first modification protein and a second modification protein. The first modification protein includes a first N intein capable of reacting with the first C intein, and a first addition component to be added to the first monomeric protein. The second modification protein includes a second N intein capable of reacting with the second C intein, and a second addition component to be added to the second monomeric protein. The first addition component and the second addition component are different addition components. The first monomeric protein and the second monomeric protein form a dimer. In the production step, the first N intein of the first modification protein reacts with the first C intein of the first monomeric protein, and then the first addition component of the first modification protein is linked to the first monomeric protein, and the second N intein of the second modification protein reacts with the second C intein of the second monomeric protein, and then the second addition component of the second modification protein is linked to the second monomeric protein.

The invention relates to a biomarker applied to early diagnosis of sepsis. The biomarker is a fibrous protein degradation product FDP / D-dimer ratio. Compared with a single index (such as PCT, D-dimer), the biomarker has the advantages that the influence of individual difference and detection error can be reduced, and the stability of a result is improved; in combination with clinical information (such as infection evidence), the ratio can be used as an independent or joint index to assist an existing scoring system (such as SOFA) in improving diagnosis accuracy.

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.

Bispecific antibodies comprising mutations that decrease homodimerization and at least one immunogenic peptide inserted into a CHI or CL domain are provided. Proteins comprising an Fc variant of a parent Fc polypeptide wherein at least one immunogenic peptide is inserted into the parent Fc polypeptide and the insertion replaces amino acids of the parent Fc polypeptide are provided. Protein dimers and antibodies comprising the proteins of the invention are also provided as are nucleic acid molecules encoding same, pharmaceutical compositions comprising same and methods of treating cancer by administrating same. Methods of producing antibodies are also provided.

To provide a curable composition which hardly generates voids during curing and has sufficient fluidity.SOLUTION: A curable composition comprising a first component represented by the following formula (1) and a second component that is a dimer, an oligomer, or a polymer obtained by polymerizing the first component, wherein when the total content of the first component and the second component is 100% by mass, the content of the first component is 40 to 90% by mass: SELECTED DRAWING: None

The application discloses a phenylboronic acid-based zwitterionic surfactant and a preparation method and application thereof, wherein the phenylboronic acid group of the phenylboronic acid-based zwitterionic surfactant includes two isomers, i.e. m BDC n AB or p BDC n AB, and alkyl chain lengths are C 10 alkyl, C 12 alkyl and C 14 alkyl, and a total of six surfactants are abbreviated as BDC n AB. BDC n AB is mixed with dodecyl-dimethyl-1,2-dihydroxypropyl ammonium chloride to prepare a mixed micelle, and an asymmetric spacer group with a dynamic covalent bond combined by a borate ester bond is generated in situ under mild conditions of normal temperature and neutral pH, thereby obtaining a pH-responsive dimer surfactant, and the dimer surfactant has a pH response interval consistent with a drug release condition for treating cancer in a human body, and can be used for preparing a drug-loaded micelle for treating cancer in the human body.

This disclosure relates to dimeric immunotherapeutics that comprise an IgG that is crosslinked with a disulfide bond. The IgG may include two heavy chains including a cysteine mutation that forms the disulfide bond. The dimeric immunotherapeutics are formed by increasing the concentration of the IgG such that spontaneous dimerization via the formation of disulfide bonds between the IgG molecules occurs over time.

The invention relates to the technical field of biology, and provides a primer group and a kit for simultaneously detecting a dengue virus and a Zika virus and application of the primer group, and the primer group is formed and comprises a primer pair 1 aiming at the dengue virus, a primer pair 2 aiming at the Zika virus and a universal LAMP (Loop-Mediated Isothermal Amplification) primer pair. When in use, target virus single-stranded RNA is used as a bridge molecule, under the catalysis of Splint R ligase, adjacent DNA probes with specific sequences are guided and connected, and a double-ring (dumbbell-shaped) structure product containing a general cyclization primer sequence is directly formed. The two key technical breakthroughs of forming a universal double-ring primer through target RNA mediated probe connection and outputting a high-specificity signal dependent on RNase H2 are realized; a dengue virus and Zika virus isothermal nucleic acid amplification detection platform which is simple and convenient to operate, rapid in reaction, high in sensitivity, strong in specificity (capable of effectively avoiding interference of primer dimers and non-specific dyes) and suitable for multiple detection is constructed, and compared with conventional fluorescent quantitative PCR, the dengue virus and Zika virus isothermal nucleic acid amplification detection platform has remarkable advantages.

The present disclosure relates to a novel fluorogenic dimer compound, useful as a probe for detection of endogenous receptors, in particular G protein-coupled receptors. The present invention provides compositions and kits comprising such compound and methods of labeling a biomolecule, comprising the step of contacting the biomolecule with the compound of the invention.

The invention relates to the field of antibody proteins, in particular to an immunoglobulin Fc dimer with a stable disulfide bond, an Fc fusion protein containing the Fc protein dimer and a calculation design method of the Fc fusion protein. The immunoglobulin Fc protein dimer comprises two protein subunits, a CH3 structural domain of each subunit contains at least one cysteine mutation, and the two protein subunits are combined through an interchain disulfide bond formed by mutation cysteine. Cysteine mutation is specifically introduced into the CH3 structural domain of the Fc region of the immunoglobulin to form a stable interchain disulfide bond, so that the problem of insufficient stability of the Fc protein dimer is solved.

A method of selectively producing oligomers can include contacting at least one antifouling agent with a first amount of at least one aluminum alkyl compound to form at least one antifouling compound comprising the following structure or dimer form thereof: (I); and adding the at least one antifouling compound, an additional amount of the at least one aluminum alkyl compound, the at least one titanate compound, and ethylene to a jet loop reactor to oligomerize the ethylene to produce one or more of 1-butene, 1-hexene, or 1-octene. (I)

The present application relates to the technical field of biotechnology, and particularly relates to a D-dimer chemiluminescence assay kit. The present application provides a D-dimer chemiluminescence assay kit, which comprises a magnetic particle suspension (immunomagnetic beads) coated with D-dimer antibody 1, alkaline phosphatase-labeled D-dimer antibody 2 (enzyme-labeled antibody) and a calibrant. The immunomagnetic beads and the enzyme-labeled antibody are prepared by chemical coupling and stored in a buffer containing a soluble high molecular material, which can effectively improve the detection sensitivity and repeatability. The kit can be used in combination with a substrate solution containing a chromogenic substrate such as adamantane and its derivative AMPPD or APS-5 for a full-automatic immune test system, and the content of D-dimer in plasma or whole blood can be determined by a chemiluminescence instrument. The kit has high detection sensitivity and good repeatability.

The present application relates to a novel antibody or antibody fragment thereof of interleukin-23 receptor, which can effectively bind IL-23R, block the binding of IL-23R and human IL-23 alpha / IL-12 beta heterodimer ligand, and has good application prospect. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3, wherein VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 3, 13 or 23, VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, 14 or 24, VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 5, 15 or 25; VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, 18 or 28, VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, 19 or 29, and VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, 20 or 30.

The invention discloses a diketopiperazine heterodimer as well as a biosynthesis method and application thereof, and belongs to the technical field of bioengineering. The biosynthesis method of the diketopiperazine heterodimer comprises the following steps: S1, culturing a recombinant cell containing P450 dimerization enzyme or a mutant thereof, and performing induced expression to obtain a whole-cell culture; and S2, adding a cyclic dipeptide substrate containing tryptophan into the whole-cell culture, carrying out a catalytic reaction, and separating and purifying the obtained product to obtain the diketopiperazine heterodimer. According to the invention, the P450 dimerization enzyme or the mutant thereof is used for catalyzing the biosynthesis of the tryptophan-containing diketopiperazine into the diketopiperazine heterodimer with different regioselectivity / stereoselectivity, the biosynthesis method is green and environment-friendly, the efficiency is high, and the variety of the diketopiperazine heterodimer is greatly expanded.

The present invention provides a hexafluoropropene dimer-containing composition as a novel mixture. Disclosed is a composition which contains hexafluoropropene dimers represented by C6F12, wherein: at least one of the hexafluoropropene dimers represented by C6F12 is a compound represented by formula (I); and the abundance ratio E / (E + Z) of the E-form among the E-form and the Z-form of the compound is more than 0.5.

A method to produce a mixture comprising poacic acid (X) and poacidiene (Y) and the resulting product-by-process. The method includes the steps of subjecting a solution of ferulic acid to a free-radical coupling reaction to yield an intermediate mixture comprising ferulic acid dehydrodimers and decarboxylating the intermediate mixture to yield a product mixture containing poacic acid (X) and poacidiene (Y).

This invention relates to a method for preparing fluorescent chiral helical nanoribbons via a hydrothermal reaction of 4-APA. The method involves adding 4-aminophthalic acid (4-APA) to deionized water, ultrasonically mixing the mixture, transferring it to a hydrothermal reactor, raising the temperature to 110–160°C within half an hour, and allowing the hydrothermal reaction to proceed for a certain time. Heating is then stopped, and the mixture is allowed to cool naturally to room temperature. Centrifugation separates the precipitate, which is the fluorescent chiral helical nanoribbon. This invention uses 4-APA as a precursor to synthesize a meta-condensed 4-APA dimer via a one-step hydrothermal reaction. Testing has confirmed that this is a fluorescent chiral helical nanoribbon, and the conditions for helical structure formation and the stability of the product's fluorescence properties are well-documented. The preparation method disclosed in this invention is simple to operate, low in cost, and environmentally friendly. The product simultaneously exhibits fluorescence and chirality, showing broad application potential in optoelectronic displays, information encryption, and other fields.